Are we ready for targeted therapy combinations in HCC?
Author:
Funder
Israel Science Foundation
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Publisher
BMJ
Subject
Gastroenterology
Reference11 articles.
1. Hepatocellular carcinoma
2. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
3. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
4. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
5. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bioinformatics analysis and experimental validation of cystathionine-gamma-lyase as a potential prognosis biomarker in hepatocellular carcinoma;BIOCELL;2024
2. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition;Cancer Cell International;2023-09-16
3. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment;Frontiers in Immunology;2023-03-16
4. Bioinformatics analysis and experimental validation of Cystathionine-gamma-lyase as a potential biomarker for prognosis in hepatocellular carcinoma;2022-12-05
5. TUG1 long non‐coding RNA enlists the USF1 transcription factor to overexpress ROMO1 leading to hepatocellular carcinoma growth and metastasis;MedComm;2020-11-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3